BioSpace News Archive

CohBar, Inc., a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced the appointment of Carol Nast as an independent director on the company’s Board, effective August 11, 2021.

Theranica, a prescribed digital therapeutics company developing advanced electroceuticals for migraine and other pain conditions, today announced that the Centers for Medicare and Medicaid Services (CMS) published its most recent Level II Healthcare Common Procedure Coding System (HCPCS), assigning Nerivio a new HCPCS Level II code K1023 “Distal Transcutaneous Electrical Nerve Stimulator, Stimulates Peripheral Nerves of the Upper Arm.”

Dr. Minnie Sarwal, NephroSant Founder, selected as winner of Lyfebulb-CSL Behring Innovation Challenge: Thriving with Transplantation NephroSant Head of Marketing Maria Lopes honored with the Maciak Award at the 2020 Transplant Games of America.

Neuromod Devices Ltd, the Irish medical device company, has announced the appointment of Ms. Susan Whichard as a non-executive board member of the company.

Noviscend Inc, a Canadian medical technology company announced today an agreement with Myriad Genetics, Inc., a leader in genetic testing and precision medicine, for the distribution of its portfolio of genetic tests.

PharmaCyte Biotech Releases Statement on Nasdaq Uplisting and Current Business Focus

Technicolor Precision BioDevices (TPB), a member of the creative technology leader Technicolor (Euronext Paris: TCH, OTCQX: TCLRY), announces a collaboration with Scope Fluidics to manufacture cartridges for their BacterOMIC system.

InferVision AI has been selected to help monitor COVID-19 variants across the European Union.

Increasing cases of cancers in all worldwide locations is estimated to boost sales opportunities in the global non-invasive cancer therapies market during the tenure of 2020 to 2030.

Fact.MR – A Market Research and Competitive Intelligence Provider: As per insights by Fact.MR, the global market for multiphoton microscopy is expected grow at a CAGR of nearly 5% over the forecast period 2021-2031, owing to the increasing adoption of multiphoton microscopy in the cancer research centres.